Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug;42(8):3069-3070.
doi: 10.1007/s10072-021-05497-4. Epub 2021 Jul 29.

Alzheimer's disease: the controversial approval of Aducanumab

Fabrizio Tagliavini  1 , Pietro Tiraboschi  1 , Antonio Federico  2
Affiliations
Editorial

Alzheimer's disease: the controversial approval of Aducanumab

Fabrizio Tagliavini et al. Neurol Sci. 2021 Aug.
No abstract available

PubMed Disclaimer

Comment in

  • More on aducanumab.
    Bugiani O. Bugiani O. Neurol Sci. 2022 Jan;43(1):713-714. doi: 10.1007/s10072-021-05663-8. Epub 2021 Oct 14. Neurol Sci. 2022. PMID: 34648104 No abstract available.

References

    1. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256(5054):184–185. https://doi.org/10.1126/science.1566067 - DOI - PubMed
    1. Panza F, Lozupone M, Logroscino G, Imbimbo BP (2019) A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol 15:73–88. https://doi.org/10.1038/s41582-018-0116-6 - DOI - PubMed
    1. FDA. FDA’s decision to approve new treatment for Alzheimer’s disease. 2021 Jul 6 [cited 2021 Jun 14]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-... . Accessed 21 Jul 2021
    1. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L et al (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537(7618):50–56. https://doi.org/10.1038/nature19323 - DOI - PubMed - PMC
    1. Biogen (2019) EMERGE and EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. Available from: https://investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b5576... . Accessed 21 Jul 2021

Publication types

MeSH terms

LinkOut - more resources